BHV3000-302 : Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine

Trial Profile

BHV3000-302 : Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs Rimegepant (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Sponsors Biohaven Pharmaceutical Holding Company
  • Most Recent Events

    • 19 Apr 2018 According to a Biohaven Pharmaceutical Holding Company media release, based on the results of BHV3000-301 and BHV3000-302 trials, the company plans for the submission of a NDA to the FDA in 2019.
    • 19 Apr 2018 According to a Biohaven Pharmaceutical Holding Company media release, data from this study will be present at the 2018 American Academy of Neurology (AAN) Annual Meeting. Also, the company plans to release this data at an Investor event.
    • 26 Mar 2018 Results presented in a Biohaven Pharmaceutical Holding Company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top